AAV	adeno-associated virus
ACL	ATP citrate lyase
ACS	acute coronary syndrome
ANGPTL3	angiopoietin-like 3
apo	apolipoprotein
ARR	absolute risk reduction
ASCVD	atherosclerotic cardiovascular disease
ASO	Antisense Oligonucleotides
BASs	Bile acid sequestrants
CA	cardiac arrest
CABG	coronary artery bypass graft
CAD	coronary artery disease
CETP	cholesteryl ester transfer protein
CKD	chronic kidney disease
CV	cardiovascular
DALI	direct adsorption of lipoproteins
DHA	docosahexaenoic acid
DM	diabetes mellitus
EPA	eicosapentaenoic acid
FDA	food and drug administration
FH	familial hypercholesterolemia
FPP	farnesyl diphosphate synthase
HDL-C	high-density lipoprotein–cholesterol
HeFH	heterozygous familial hypercholesterolemia
HF	heart failure
HIV	human immunodeficiency virus
HMG-CoA	hydroxymethylglutaryl-CoA
HoFH	Homozygous familial hypercholesterolemia
hsCRP	high sensitivity C-reactive protein
HTG-AP	hypertriglyceridemia-associated acute pancreatitis
IDOL	inducible degrader of LDL receptors
IFPTA	immunogenic fused PCSK9-tetanus
LDL-C	low-density lipoprotein–cholesterol
LDLRs	LDL receptors
Lp(a)	lipoprotein(a)
LPL	lipoprotein lipase
Lp-PLA2	phospholipase A2
LVEF	left ventricular ejection fraction
LXR	liver X receptor
MACEs	major adverse cardiovascular events
MI	Myocardial infarction
MTP	microsomal triglyceride transfer protein
NGAT	acyl-CoA:1,2-diacylglycerol acyltransferase
NNT	Number Needed to Treat
NPC1L1	Niemann–Pick C1-like 1
NYHA	New York Heart Association
OM3FAs	Omega-3 fatty acids
PAD	peripheral artery disease
PCI	percutaneous coronary intervention
PCSK9	proprotein convertase subtilisin/kexin type 9
PPARs	peroxisome proliferator-activated receptors
PUFA	polyunsaturated fatty acid
PVD	polyvascular disease
RCT	randomized clinical trial
RISC	RNA-induced silencing complex
RRR	relative risk reduction
SCD	sudden cardiac death
TGRL	triglyceride-rich lipoprotein
VLDL	very low-density lipoproteins